AHMET GULMEZ, HAKAN HARPUTLUOGLU
Eurasian Journal of Medical Investigation - 2023;7(3):209-214
Objectives: The pan-immune-inflammation value (PIV) is an easily calculable immune marker based on blood labora tory tests to predict prognosis in cancer patients. The primary aim of this study is to evaluate the prognostic value of PIV in metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer (mBC) patients treated with dual block with pertuzumab. Methods: This retrospective study evaluated the relationship between PIV and other prognostic markers, progression free survival (PFS), and overall survival (OS) in HER2-positive metastatic BC patients treated with dual block with per tuzumab. PIV was calculated as follows: neutrophil count (109 /L) × platelet count (109 /L) × monocyte count (109 /L)/ lymphocyte count (109 /L). Results: A total of 61 patients with mBC were included in this study. According to cutoff value for PIV, 31 (50.8%) and 30 (49.2%) patients fell into PIV-low <418,61 and PIV-high ?418,61 groups, respectively. As a result of univariate analysis, high PIV was associated with worse outcome, which was statistically significant for both OS and PFS. Similarly, other IPMs were also statistically significantly associated with survival. Conclusion: This study demonstrated that pre-treatment PIV may be a prognostic biomarker in metastatic HER2-posi tive BC patients treated with pertuzumab.
